ERBB2 and neoplasm: Moreover, ERBB2 was overexpressed in 29.1% (16/55) [22], 80% (60/75) [23], and 82.4% (28/34) [19] of patients with ECC, and ERBB2 is closely associated with tumor grade, higher rates of distant metastases, and poor survival of ECC patients with lymphatic invasion and perineural invasion [22,23].